A Phase 1/2 interventional study of STP705 in Facial isSCC, sponsored by Sirnaomics. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Sirnaomics · Phase 1/2, Interventional, and Treatment
The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Open label, dose escalation to evaluate safety.
Evaluate safety, tolerability, and efficacy of various doses of STP705 administered as intralesional injection in subjects with facial isSCC.
There will be 3 cohorts of 10 subjects each. Enrolled subjects will receive STP705 once weekly for 6 weeks. The lesion will be excised 60 days after.
Sirnaomics is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 2 (22%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria: Subjects are required to meet all of the following criteria for enrollment into the study:
EXCLUSION CRITERIA
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
STP705 will be administered once weekly for 6 weeks
Drug: STP705
STP705 will be administered once weekly for 6 weeks
Drug: STP705
STP705 will be administered once weekly for 6 weeks
Drug: STP705
STP705 targets TGFB-1 and COX-2 mRNA respectively.
Also known as: STP705 Powder for Injection
Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment
Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review
Time frame: 21 weeks
Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period.
A Baseline assessment of lesion size was made by the investigator at T1 (first treatment visit). This was measured by widest width and longest length using a caliper or a ruler as deemed by the investigator's judgement. The change in size was assessed every visit until the surgical excision of isSCC at the EOT Visit.
Time frame: 21 weeks
| Milestone | STP705 30ug | STP705 60ug | STP705 90ug |
|---|---|---|---|
| Started | 9 | 0 | 0 |
| Completed | 8 | 0 | 0 |
| Not completed | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
Histological clearance will be defined as the absence of detectable evidence of isSCC tumor cell nests determined by pathology review
| Participants | STP705 30ug | STP705 60ug | STP705 90ug |
|---|---|---|---|
| Proportion of Participants With Histological Clerance of Treated isSCC Lesion at the End of Treatment | 6 | 0 | 0 |
A Baseline assessment of lesion size was made by the investigator at T1 (first treatment visit). This was measured by widest width and longest length using a caliper or a ruler as deemed by the investigator's judgement. The change in size was assessed every visit until the surgical excision of isSCC at the EOT Visit.
| millimeters squared (mm2) | STP705 30ug | STP705 60ug | STP705 90ug |
|---|---|---|---|
| Change in Size of the Treated isSCC Lesion Over the Pre-excision Treatment Period. | 11.4 (0 to 37) | — | — |
Collected over for example, "from enrollment until end of follow-up, up to 18 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| STP705 30ug | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| STP705 60ug | — | — | — |
| STP705 90ug | — | — | — |
| Event | STP705 30ug | STP705 60ug | STP705 90ug |
|---|---|---|---|
| Injection site indurationGeneral disorders | 2/9 | — | — |
| Vision blurredEye disorders | 1/9 | — | — |
| Urinary tract infectionInfections and infestations | 1/9 | — | — |
| Injection site painGeneral disorders | 1/9 | — | — |
The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
| Age, Categorical(Participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 0 | 0 | 1 |
| >=65 years | 8 | 0 | 0 | 8 |
| Age, Continuous(years) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| Median | 70 (53 to 89) | — | — | 70 (53 to 89) |
| Sex: Female, Male(Participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| Female | 2 | 0 | 0 | 2 |
| Male | 7 | 0 | 0 | 7 |
| Ethnicity (NIH/OMB)(Participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 8 | 0 | 0 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 9 | 0 | 0 | 9 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| United States | 9 | — | — | 9 |
| Facial isSCC lesion(Participants) | STP705 30ug | STP705 60ug | STP705 90ug | Total |
|---|---|---|---|---|
| Count of participants | 9 | 0 | 0 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Mar 2023, 7 months.
Results were first posted in Oct 2026, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
The Sponsor terminated the study at the conclusion of Cohort A. Cohort B and Cohort C were not initiated. The Sponsor terminated the study before reaching the planned 30 subjects for corporate strategic reasons not related to safety.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cotsiranib
Sirnaomics